Allakos (ALLK.US) is down more than 77% today after releasing disappointing results from clinical trials of its drug AK006. The drug was intended to treat Chronic Spontaneous Urticaria (CSU), but the phase 1 trial results did not demonstrate sufficient therapeutic activity. As a result, the company has decided to abandon the project, which was one of its leading programs. Following the discontinuation of the project, the company announced it will lay off 75% of its workforce and will begin a review of available strategies to find a new alternative for its future operations.
Source: xStation
Who Will Surprise With Earnings Next Week? (07.08.2026)
US OPEN: Shallow rebound in the shadow of a weak labor market
Dollar and Nasdaq facing a key test
Market Wrap: Tech lifts Europe to new record highs! Metals keep rallying despite stagnant USD (07.08.2026)